SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-114234
Filing Date
2022-11-03
Accepted
2022-11-03 08:40:14
Documents
13
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2229607d1_8k.htm   iXBRL 8-K 26422
2 EXHIBIT 99.1 tm2229607d1_ex99-1.htm EX-99.1 70251
  Complete submission text file 0001104659-22-114234.txt   277316

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clrb-20221103.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20221103_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20221103_pre.xml EX-101.PRE 22597
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2229607d1_8k_htm.xml XML 3494
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

IRS No.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36598 | Film No.: 221356411
SIC: 2834 Pharmaceutical Preparations